Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35762378/
1 World Health Organization, Geneva, Switzerland. 2 Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance, Tufts University School of Medicine, Boston, Massachusetts, USA. 1 World Health Organization, Geneva,...
Summary: Monitoring HIVDR remains pivotal to ensure countries attain and sustain the global goals for ending HIV as a public health threat by 2030.
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35762503/
doi: 10.1093/jac/dkac207. Online ahead of print. 1 Service de Médecine Interne, APHP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France. 2 INSERM, U1016, CNRS, UMR8104, Institut Cochin, Paris, France. 3 INSERM SC10-US19, Villejuif,...
Conclusions: Dolutegravir-based and darunavir-based regimens initiated during PHI strongly and similarly decreased the blood reservoir size. Considering the rapid viral suppression during a period of high HIV-1 transmission risk, dolutegravir-based regimens are a major first-line option.
Dispensing of HIV and Hepatitis C Antivirals During COVID-19: An Interrupted Time-Series Analysis of U.S. National Data - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35738958/
U.S. dispensing of DAAs to treat HCV fell at the start of the U.S. COVID-19 outbreak and has yet to fully recover to prepandemic levels. Addressing barriers to care is...
Conclusions: U.S. dispensing of DAAs to treat HCV fell at the start of the U.S. COVID-19 outbreak and has: yet to fully recover to prepandemic levels. Addressing barriers to care is crucial to reaching national HIV and hepatitis C elimination goals.
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35713430/
Switching dual therapy with dolutegravir (DTG) plus rilpivirine (RPV) was assessed in the SWORD-1 and SWORD-2 studies. Real-life data regarding the immunological impact of this approach on CD4+ and CD8+...
Relevance: In patients with controlled treatment, dual therapy with DTG plus RPV slightly improved the immune status during the first 48 weeks after switching, not only in terms of CD4 T-cell count but also in terms of CD8 T-cell count, with persistently high rates of viral control.
Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35730213/
doi: 10.1111/hiv.13352. Online ahead of print. 1 Swiss Tropical and Public Health Institute, Basel, Switzerland. 2 Molecular Virology Group, Department of Biomedicine, Basel, Switzerland. 3 University of Basel, Basel, Switzerland....
Conclusions: We observed no negative impacts and potential moderate improvements with DTG, providing further support for the rollout of DTG.